Can bisphenol A interfere with hormone and metabolic receptor signaling?

Bisphenol A (BPA) is a pervasive environmental endocrine disruptor that interferes with multiple nuclear and membrane receptors, leading to systemic steroidogenic and cardiometabolic dysfunction.

Receptor-binding mechanisms

• Estrogen pathways: BPA acts as a weak agonist for classical ERα and ERβ (affinity 1,000- to 10,000-fold lower than 17β-estradiol) but binds with high nanomolar affinity ($K_D \approx 5.5$ nM) to estrogen-related receptor-γ (ERRγ) and triggers rapid non-genomic signaling via membrane-associated GPER.
• Androgen and thyroid antagonism: It behaves as an antagonist at the androgen receptor ($IC_{50} \approx 1\text{–}2$ µM), impairing nuclear translocation, and acts as a competitive antagonist at thyroid receptors ($K_i \approx 200$ µM), suppressing thyroid hormone-responsive genes.
• Metabolic signaling: BPA acts as a low-affinity agonist for PPARγ, stimulating adipocyte differentiation and lipid accumulation.

Steroid and cardiovascular consequences

• Testosterone suppression: In males, exposure is associated with primary testicular dysfunction and hypogonadism, characterized by reduced total testosterone alongside elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• Leydig cell cholesterol depletion: Mechanistically, BPA upregulates ApoA1 expression and accelerates reverse cholesterol transport in Leydig cells. This process drains local cholesterol stores, directly depriving the cells of the precursor required for testosterone synthesis.
• Cardiometabolic pathology: Receptor interference (especially via ERβ) alters calcium handling and induces endothelial dysfunction. Large clinical cohorts link elevated serum and urinary BPA levels to increased risks of cardiac arrhythmias, coronary artery disease, peripheral arterial disease, and heart failure.

Bottom line

• BPA systematically disrupts steroid hormone and cardiovascular regulation through multi-receptor agonism and antagonism. For aging males, this exposure is clinically relevant as it impairs testosterone synthesis—via novel ApoA1-mediated Leydig cell cholesterol depletion—while simultaneously elevating the risk of coronary and peripheral vascular disease.